摘要
目的探讨血必净注射液活性成分、靶标与新型冠状病毒肺炎之间存在的联系,为血必净注射液治疗新型冠状病毒肺炎以及后期的药物开发提供理论依据。方法从"中药系统药理学数据库与分析平台"和已发表的文献中整合血必净注射液的有效成分和对应靶标,用Cytoscape软件构建网络并进行分析,使用DAVID和STRING数据库对得到的靶点进行通路富集分析。结果①通过数据库和文献检索,得到血必净注射液中的有效化合物成分共22个,共对应了504个潜在作用靶点。②与新型冠状病毒的受体血管紧张素转化酶2(ACE2)共表达的靶点进行交集,得到70个交集蛋白,提示血必净注射液可能通过这70个蛋白对新型冠状病毒肺炎起治疗作用。③靶点蛋白调控的通路主要集中在HIF-1信号通路、PI3K-Akt信号通路等一系列的通路中。结论血必净注射液对于新型冠状病毒肺炎的治疗体现了中药多成分、多靶点的整体调控作用,可能通过对70个能与ACE2互作的蛋白,调控与疾病发生发展相关联的通路,缓解炎症反应,抑制病毒复制,从而起到抗病毒的作用。
Objective To explore the relationship between the active components and targets of Xuebijing injection and coronavirus disease 2019(COVID-19),and to provide theoretical basis for Xuebijing injection in the treatment of COVID-19 and new drug development.Methods The active compounds of Xuebijing injection and corresponding targets of each compounds were obtained from the TCMSP database and published researches,and the network was constructed and analyzed by Cytoscape.GO and KEGG analyses were performed on the obtained targets by DAVID and STRING databases.Results①From the database and published researches,22 compounds in Xuebijing injection were obtained,corresponding to 504 potential targets.②Among them 70 proteins were intersected with targets co-expressed with angiotensin-converting enzyme 2(ACE2),a receptor of the novel coronavirus,suggesting that Xuebijing injection may play a therapeutic role on COVID-19 through these 70 proteins.③These target proteins regulate a series of signaling pathways,such as HIF-1 signaling pathway and PI3 K-Akt signaling pathway.Conclusion Xuebijing injection reflected an overall regulation of multi-components and multi-targets of traditional Chinese medicine for the treatment of COVID-19.It may realize the anti-virus function by regulating the pathways related to the development of disease through 70 proteins that can interact with ACE2 to relieve inflammation and inhibit virus replication.
作者
施烜
魏娟
刘美云
金小红
周焕平
朱万莉
冯迪
杨浩
吕欣
SHI Xuan;WEI Juan;LIU Meiyun;JIN Xiaohong;ZHOU Huanping;ZHU Wanli;FENG Di;YANG Hao;LYU Xin(Department of Anesthesiology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China)
出处
《上海中医药杂志》
2020年第4期46-52,共7页
Shanghai Journal of Traditional Chinese Medicine
基金
国家自然科学基金面上项目(81671947)
作者简介
施烜,男,博士研究生,主要从事急性肺损伤的机制及保护相关研究工作。;通信作者:吕欣,主任医师,教授,博士研究生导师。E-mail:xinlvg@126.com
